SQZ Biotechnologies Company SQZ
Set alert
As of Jul 3, 1:00 PM ET
52-week range unavailable
- Open
- 0.40995
- Prev close
- 0.435
- Mkt cap
- 12.83M
- Vol
- 30.14M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.38
- High
- 0.5678
- Forward P/E
- -0.62
- Beta
- 2.71
- Short ratio
- 27.26
- Inst. own
- 66.58%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 3, 2023
- 50-d avg
- 0.509346
- 200-d avg
- 1.13
- 1y target
- 19.00
Key statistics
- Market cap
- 12.83M
- Enterprise value
- -6.50M
- Trailing P/E
- 0.00
- Forward P/E
- -0.62
- PEG ratio
- 0.00
- Price / sales
- 0.69
- Price / book
- 0.32
- EPS (TTM)
- -2.16
- Beta
- 2.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 18.61M
- Revenue growth
- 0.00%
- Free cash flow
- -37.69M
- Total cash
- 39.87M
- Total debt
- 24.50M
- Return on equity
- -104.93%
- Shares outstanding
- 29.49M
- Short % of float
- 3.03%
- 50-day average
- 0.509346
- 200-day average
- 1.13
Analyst view
Consensus: buy
- Target (low)
- 4.00
- Target (mean)
- 19.00
- Target (high)
- 34.00
Next earnings
Aug 3, 2023
Expected Aug 3, 2023. Consensus EPS estimate -0.60.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 3, 2023 | Jun 1, 2023 | -0.60 | — | — | — |
| May 10, 2023 | Mar 1, 2023 | -0.54 | — | — | — |
| Mar 22, 2023 | Dec 1, 2022 | -0.80 | — | — | — |
| Nov 9, 2022 | Sep 1, 2022 | -0.89 | — | — | — |
| Aug 4, 2022 | Jun 1, 2022 | -0.79 | — | — | — |
| May 10, 2022 | Mar 1, 2022 | -0.71 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| Dec 1, 2022 | Chardan Capital | main | — | Buy |
| Dec 1, 2022 | B of A Securities | down | Buy | Underperform |
| Nov 10, 2022 | Chardan Capital | main | — | Buy |
| Oct 20, 2022 | HC Wainwright & Co. | init | — | Buy |
| Oct 6, 2022 | BTIG | main | — | Buy |
About SQZ Biotechnologies Company
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- sqzbiotech.com
News
- Serica Energy cuts 2026 production guidance as brokers retain 'buy' ratings
- Serica Energy maintains cash flow guidance despite Triton delay
- Serica Energy gets Jefferies 'buy' rating and 320p price target
- Reviewing Galectin Therapeutics (NASDAQ:GALT) & SQZ Biotechnologies (NYSE:SQZ)
- Serica Energy says it won't raise bid for Pharos
- Serica Energy shares rise on bond financing talk
- Financial Comparison: SQZ Biotechnologies (NYSE:SQZ) vs. Cortexyme (NASDAQ:CRTX)
- Cortexyme (NASDAQ:CRTX) and SQZ Biotechnologies (NYSE:SQZ) Critical Review
- Head to Head Contrast: NKGen Biotech (NYSE:NKGN) and SQZ Biotechnologies (NYSE:SQZ)
- Head to Head Comparison: NKGen Biotech (NYSE:NKGN) versus SQZ Biotechnologies (NYSE:SQZ)
Your note
Sign in to keep a note on SQZ — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARMON R. SHAREI IRREVOCABLE GST TRUST OF 2016 | Trustee | Conversion of Exercise of derivative security | Nov 2, 2020 | 385,891 |
| CAPASSO RICHARD | Officer | Sale | Aug 14, 2022 | 0 |
| INVUS PUBLIC EQUITIES ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 2, 2020 | 0 |
| JENSEN KLAVS F. PH.D. | Director | Purchase | May 24, 2022 | 353,309 |
| KNOPF LAWRENCE J | General Counsel | Stock Award(Grant) | Jun 29, 2022 | 1,938 |
| POLARIS MANAGEMENT CO. VII, L.L.C | Beneficial Owner of more than 10% of a Class of Security | Purchase | Nov 2, 2020 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Temasek Holdings (Private) Limited | 9.35% | 2,758,169 | 1.20M | Mar 30, 2023 |
| American International Group, Inc. | 8.54% | 2,517,173 | 1.09M | Mar 30, 2023 |
| Artal Group S.A. | 5.45% | 1,606,309 | 698.74K | Mar 30, 2023 |
| Maverick Capital Ltd. | 3.57% | 1,051,771 | 457.52K | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 3.19% | 941,752 | 409.66K | Mar 30, 2023 |
| Stifel Financial Corporation | 2.96% | 874,326 | 380.33K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.23% | 657,886 | 286.18K | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 0.82% | 241,040 | 104.85K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.28% | 83,721 | 36.42K | Feb 27, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.21% | 62,400 | 27.14K | Dec 30, 2022 |
| iShares Micro Cap ETF | 0.18% | 53,703 | 23.36K | Feb 27, 2023 |
| Vanguard Balanced Index Fund | 0.07% | 21,128 | 9.19K | Dec 30, 2022 |